How the COVID-19 Vaccine for Children Differs From Adults’

 

Key Points:

  • Pfizer recently announced its vaccine for children is more than 90% effective.
  • In vitro diagnostics company Todos Medical announced the launch of their new COVID-19 antibody blood test which will allow unvaccinated and vaccinated people to monitor their immunity levels to the virus.
  • Healthcare professionals weigh the utility of this type of testing given the amount of at-risk people they interact with on a daily basis.

Commentary:

The next step in the fight against the COVID-19 virus has been the approval of the vaccine for children. Most recently, Pfizer announced that the vaccine that was approved for children is 90 percent effective against COVID-19. Now that the children’s vaccine is here, what was its development like compared to the one for adults? Was it easier or harder? We sat down with Gerald Commissiong, CEO of Todos Medical, to get insight into how the industry has approached the task of vaccine research and testing for different demographics.

MarketScale also asked Commissiong about the recent announcement by Todos about the launch of its new COVID-19 antibody blood test, which will allow unvaccinated and vaccinated people to monitor their immunity levels to the virus. What role will such a test play in the larger ecosystem of COVID treatment and mitigation?

Abridged Thoughts:

Initially, it was thought, although it’s not clear why it was thought, that children were not going to be affected by COVID in the same manner that adults were. As a result of that, the primary focus was really adults who were traveling from place to place, country to country who can spread the disease.

And the focus was on being able to really get people back into the office, back to work. What we found, obviously, is that getting back to work requires children to be able to get back to school. And so as we’ve made progress with the initial set of vaccines and really an undefined, unknown dosing schedule that has been figured out through real world decisions by different countries to do different things than the clinical trials, that kind of approach could have been disastrous in children because we know that their immune systems are not anywhere near as developed and that potentially impacting their immune systems in a robust way very early on in development could have significant long term impacts.

Because of that, I think correctly, everyone focused on developing an effective and safe vaccine for adults and then began to think through how to use the data from adults to develop for kids. There was some acceleration in the 12 to 15 year age gap with the Pfizer vaccine. I think that is being rethought extensively now, given some of the data and the younger kids where there is no evidence of myocarditis with a much lower dosing schedule that could potentially be even further reduced with lengthening the spacing between doses.

More Stories Like This:

Should the COVID-19 Vaccine’s Intellectual Property Be Accessible for Everyone?

Is It Time to Revamp the Drug Development Pipeline?

Follow us on social media for the latest updates in B2B!

Image

Latest

Listen Carefully, Respond Creatively
April 12, 2024

In this captivating episode of the Fans First series, Jesse Cole, the mastermind behind the Savannah Bananas, delves into the transformative business philosophy of “listen carefully, respond creatively.” This approach has not only skyrocketed the Savannah Bananas to fame but also serves as a universal blueprint for revolutionizing customer service and engagement across all sectors. […]

Read More
Stacey Childress, Senior Advisor at McKinsey and Company, discusses higher ed
Bold Measures are Needed to Improve Investment in Higher Education
April 12, 2024

The stakes for higher education have never been higher as the educational landscape sees rapid evolution. As universities and colleges grapple with the dual challenges of technological disruption and increasing demands for accessible, quality education, the question of how best to implement investment in higher education becomes a priority. This debate has been ignited […]

Read More
wake up healthy
Hey, it’s 9 am… Wake up Healthy with 9amHealth!
April 12, 2024

Healthcare Rethink host Brian Urban explores ways to wake up healthy and stay healthy with his guest, Dr. Avantika Waring, MD, the Chief Medical Officer, at 9amHealth. This episode delves into the transformative approach to healthcare delivery championed by 9amHealth. Dr. Waring’s journey from a humanities student with a love for French to a […]

Read More
public safety and security
Strengthen Public Safety and Security: Modernize Radio Communication for Better Field Response
April 11, 2024

The importance of radio communication within public safety and security operations remains unbeaten in an era dominated by digital transformation. This medium, essential for over a century, continues to be the lifeline for responders on the front lines. From ensuring the safety of field agents to facilitating real-time critical information flow and enhancing situational […]

Read More